Novel TLR7 agonist demonstrates synergistic antitumor activity with anti-PD-1 antibodies
Sep. 5, 2023
Researchers from Bristol Myers Squibb Co. recently discussed the discovery and preclinical characterization of a series of Toll-like receptor 7 (TLR7) agonists with potential as anticancer drug candidates.
